Faculty profile

Aruz Mesci

Back to faculty

Assistant ProfessorDepartment of Radiation OncologyUniversity of Toronto

Aruz Mesci

Assistant Professor

Department of Radiation Oncology

Temerty Faculty of Medicine

University of Toronto

Toronto, Ontario, Canada

Supervision signals

Professors usually supervise graduate students in their department's programs.
26 publications in the last five years, latest in 2026.
Senior (last) author on 3 recent papers, a sign of leading a research group.

These signals come from public records, including federal and provincial funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

865

Citations

282

Collaborators

Grants

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

University Profile

Search on Google Scholar

Search on ResearchGate

iDORCID OpenAlex

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Read how they describe their research on their University of Toronto profile.

Latest papers

Pembrolizumab and stereotactic body radiotherapy combined in advanced hepatocellular carcinoma post sorafenib - A phase II trial (PEMRAD).
JHEP reports : innovation in hepatology · 2026
Integrity of delivered dose in temporally fractionated lattice radiotherapy amid anatomical changes and setup uncertainties.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2026
Clinical and molecular features associated with the presence of brain metastases and survival in patients with advanced thyroid cancer.
The oncologist · 2026

All 46 publications

Latest funding

Lattice Radiation Therapy versus Conventional Radiation Therapy for the Palliation of Large Tumors (LATTICE-PAL)
CIHR · 2026 · Co-investigator
$960,076
A randomised controlled trial of Standard Of Care versus RadioAblaTion in Early Stage HCC (The SOCRATES HCC Study)
CIHR · 2025 · Co-investigator
$210,000

All 2 grants and awards

46 publications.

Pembrolizumab and stereotactic body radiotherapy combined in advanced hepatocellular carcinoma post sorafenib - A phase II trial (PEMRAD).

O'Kane GM, Mesci A, Jang RW, Barry A, Bocaya CM, Boukhaled GM, Acton H, Doddington D, Rodrigo R, Chan LML, Noamani B, Harvey H, Elia A, Law R, Prince R, Doherty M, Dodd A, Wong DK, Wang L, Wang BX, Chen EX, Dawson LA, Knox JJ

JHEP reports : innovation in hepatology20266 citationsOpen Access

DOI: 10.1016/j.jhepr.2025.101658 PMID: 41585952

Integrity of delivered dose in temporally fractionated lattice radiotherapy amid anatomical changes and setup uncertainties.

Liu N, Parent A, Tsang Y, Heng VJ, Wong P, Kirsch DG, Mesci A, Malik N, Chung P, Keilty D, Hahn E, Hodgson D, Tsai J, Dawson LA, Lukovic J, Serban M

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology20261 citations

DOI: 10.1016/j.radonc.2026.111457 PMID: 41765185

Clinical and molecular features associated with the presence of brain metastases and survival in patients with advanced thyroid cancer.

Barron CC, Megid TBC, Deng Y, Sugumar V, Ladak S, Mesci A, Yan M, Lukovic J, Krzyzanowska MK, Sawka AM, Mete O, Ma LX

The oncologist2026Open Access

DOI: 10.1093/oncolo/oyag211 PMID: 42213058

Cross-Cancer Analysis Reveals a Distinct Pattern of Immune Modulation During Curative Radiation Therapy.

Said BI, Boukhaled GM, Lok BH, Lukovic J, Mesci A, Waldron J, Wong P, Wang BX, Brooks DG, Milosevic M

International journal of radiation oncology, biology, physics2026Open Access

DOI: 10.1016/j.ijrobp.2025.08.039 PMID: 40970850

Stereotactic Body Radiation Therapy for Renal Tumors: A Prospective Phase 2 Clinical Trial.

Glicksman RM, Winter J, McPartlin A, Santiago AT, Wang K, Bernstein J, Dang J, Tsui G, Chung P, Mesci A, Gutierrez Valencia E, Raman S, Berlin A, Catton C, Bayley A, Warde P, Krishna S, Finelli A, Hamilton RJ, Pace KT, Kitchlu A, Helou J

International journal of radiation oncology, biology, physics2026Open Access

DOI: 10.1016/j.ijrobp.2025.11.005 PMID: 41290048

Simulation-Free Single-Fraction High-Dose Radiotherapy for Non-Spine Bone and Soft Tissue Metastases.

Javor J, Mesci A, Wong P, Cummings BJ, Safavi A, Dawson LA, Wong RK, Delposo-Lee K, Chelvarajah R, Agrawal A, Wattakiyanon N, Rosewall T, Tadic T, Taylor E, Tsai CJ

Practical radiation oncology2026

DOI: 10.1016/j.prro.2026.06.009 PMID: 42413576

Prospective evaluation of liver cancer volumes on non-contrast 1.5 T MR Linac imaging.

Glynn AM, Saha S, Gerard IJ, Velec M, Stanescu T, Martinez JD, Munoz-Schuffenegger P, Hosni A, Mesci A, Yan M, Rocca C, Shessel A, Kim TK, Dawson LA

Clinical and translational radiation oncology2026Open Access

DOI: 10.1016/j.ctro.2026.101110 PMID: 41631035

Transition from Oncologist- to Therapist-Led MRI-Guided Ultra-Hypofractionated Adaptive Prostate Radiation Therapy: Evaluation of Early Clinical Outcomes.

Moreira A, Rosewall T, Dang J, Kim A, Santiago AT, Mesci A, Gutierrez E, Bayley A, McPartlin A, Glicksman RM, Berlin A, Winter J, Li W, Chung P

Current oncology (Toronto, Ont.)2026Open Access

DOI: 10.3390/curroncol33070398 PMID: 42505200

Radiotherapy for the management of bone metastases in differentiated thyroid cancer.

Faulkner C, Mesci A, Alfadli F, Brierley JD, Tsang R, Ye XY, Mete O, Ma L, Barron C, Krzyzanowska MK, Lukovic J

Clinical and translational radiation oncology2026Open Access

DOI: 10.1016/j.ctro.2026.101139 PMID: 41868579

Evaluating the environmental Effects of Simulation-Free radiation therapy for palliative treatments.

Lee J, Javor J, Tsai CJ, Cummings B, Mesci A, Kong V, Millar BA, Dawson LA, Wong R, Delposo-Lee K, Taylor E, Wong P

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology2026

DOI: 10.1016/j.radonc.2026.111472 PMID: 41812863

Profile data last refreshed on September 29, 2026 from the university directory, publication records and public research funding records.

Something wrong or missing on this profile? Suggest a correction

Aruz Mesci

Research

Latest papers

Latest funding

Pembrolizumab and stereotactic body radiotherapy combined in advanced hepatocellular carcinoma post sorafenib - A phase II trial (PEMRAD).

Integrity of delivered dose in temporally fractionated lattice radiotherapy amid anatomical changes and setup uncertainties.

Clinical and molecular features associated with the presence of brain metastases and survival in patients with advanced thyroid cancer.

Cross-Cancer Analysis Reveals a Distinct Pattern of Immune Modulation During Curative Radiation Therapy.

Stereotactic Body Radiation Therapy for Renal Tumors: A Prospective Phase 2 Clinical Trial.

Simulation-Free Single-Fraction High-Dose Radiotherapy for Non-Spine Bone and Soft Tissue Metastases.

Prospective evaluation of liver cancer volumes on non-contrast 1.5&#xa0;T MR Linac imaging.

Transition from Oncologist- to Therapist-Led MRI-Guided Ultra-Hypofractionated Adaptive Prostate Radiation Therapy: Evaluation of Early Clinical Outcomes.

Radiotherapy for the management of bone metastases in differentiated thyroid cancer.

Evaluating the environmental Effects of Simulation-Free radiation therapy for palliative treatments.

Lattice Radiation Therapy versus Conventional Radiation Therapy for the Palliation of Large Tumors (LATTICE-PAL)

A randomised controlled trial of Standard Of Care versus RadioAblaTion in Early Stage HCC (The SOCRATES HCC Study)

Frequent collaborators

James Carlyle

Jelena Lukovic

Stanley Liu

Laura Dawson

Peter Chung

Andrew Makrigiannis

Philip Wong

Ali Hosni

Michael Yan

Alejandro Berlin

Ozgur Mete

Andrew McPartlin

David Goldstein

Rebecca Wong

Andrew Bayley

Lee-Hwa Tai

Charles Catton

Edward Chow

Edward Taylor

John Kim

Tara Rosewall

Ur Metser

Fayez Quereshy

Chaya Shwaartz

C. Tsai

Lucy Ma

Nicole Hong

Negar Ahmadi

Mantaj Brar

Peter Stotland

Laura Snell

Sayf Gazala

Brittany Greene

Carmine Simone

Adena Scheer

Dhruvin Hirpara

Najib Safieddine

Shiva Jayaraman

Trevor Reichman

Amanda Roberts

Prospective evaluation of liver cancer volumes on non-contrast 1.5 T MR Linac imaging.